Photodynamic therapy using SnET2 for basal cell nevus syndrome: A case report

Clinical Therapeutics

Volumn 19, Issue 4, 1997, Pages 639-641

  Rifkin, Robert ^a,c   Reed, Barbara ^a   Hetzel, Fred ^b   Chen, Kun ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b HealthOne   (United States)

^c NONE   (United States)

Author keywords

Basal cell carcinoma; Basal cell nevus syndrome; Photodynamic therapy; SnET2

Indexed keywords

PHOTOSENSITIZING AGENT; PURLYTIN; TIN ETHYLETIOPURPURIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL CELL NEVUS SYNDROME; CASE REPORT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHOTODYNAMIC THERAPY;

EID: 0030764969     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80089-6     Document Type: Article

References (7)

1. Henderson B, Dougherty T. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
2. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res. 1976;36: 2326-2331.
3. Morgan AR, Garbo GM, Keck RW, Selman SH. Tin etiopurpurin dichloride: An alternative to DHE? Soc Photo-Opt Instr Eng. 1988;847:172-179.
4. Morgan AR, Selman SH. New photosensitizers for the photodynamic therapy of tumors. Drugs Future. 1988;13:1073-1082.
5. Snyder AB, Kaplan MJ. Photodynamic therapy: From research to the practicing physician. Cope. 1995;11:6-8.
6. Doiron DR. Future directions in photodynamic therapy. Facial Plast Surg. 1989; 6:190-192.
7. Krown SE, Metroka C, Wernz C. Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol. 1989;7:1201-1207.